The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
about
Applications of CYP450 testing in the clinical settingInterethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individualsA Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic InformationCharacterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestaneDrug-Resistant Epilepsy: Multiple Hypotheses, Few AnswersThe 'apparent clearance' of free phenytoin in elderly vs. younger adultsPharmacogenetics of Anti-Diabetes Drugs.Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosingGenetic and nongenetic factors associated with warfarin dose requirements in Egyptian patientsPharmacogenetics in drug regulation: promise, potential and pitfalls.Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian populationCYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicityPossible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsyClinical relevance of genetic polymorphisms in the human CYP2C9 gene.Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules.Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.The role of drug-metabolising enzymes in clinical responses to chemotherapy.Genetic association studies in epilepsy pharmacogenomics: lessons learnt and potential applications.Translational research: Basic science to health care. Way forward.Association of CYP2C9*2 with bosentan-induced liver injury.Epilepsy pharmacogenetics.Cytochrome P450 2C9-CYP2C9.From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.Pharmacogenomics and epilepsy: the road ahead.Clinical association between pharmacogenomics and adverse drug reactions.CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.Pharmacogenomic profiling in postmarketing surveillance: prospects and challenges.Biomarkers for antiepileptic drug response.CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population.Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.
P2860
Q24621760-172C3310-9C93-4F80-BE37-D2EE6A2D09F1Q28237144-CB58E00E-06E5-468D-912B-583B4557301AQ28468396-3CCDE7E6-46AF-433B-8E76-CEE427F456DDQ30939373-33FC2732-CFEC-4A4C-BF23-0BEDF1234DD1Q33664128-058049EA-413D-4DEC-91C2-C38F9EF9D3BFQ33777963-497C7147-DA3A-4E81-803C-54B906B831A1Q33875271-0686E68C-80BF-47C9-A23E-F38F3CB6AD24Q34019379-7D6C4996-D0CE-4C4C-AEFF-50C026118B21Q34181995-C25924F9-E8AD-4ED3-AAA9-88DC505A3CE9Q34389432-3EF67E3F-A2A9-4334-80D9-707DF0256517Q34571746-6028AE49-234C-40D1-95B3-9519D97574A5Q35038052-280E522E-E05A-408E-8CDE-5B934769CC54Q35073509-28E93806-FCB9-4C64-A453-A81165E324F5Q35117277-B8429D97-99AE-47B7-B6FE-F47EBA814B70Q35351731-84CDAA3B-4C79-4324-923C-B2F665256551Q35594567-2951EBFA-FD78-420F-9956-82B051ED8623Q35661209-15C76E9A-6FE2-4972-A70D-C182C1A0976BQ35753607-B1F28E91-94AE-4FA9-89A9-F1A81F016B01Q35873680-064E105E-DDCB-4C1B-A664-BD83B56D3F12Q35876954-52866E85-1477-40AC-8510-117855CD4944Q36018001-61C9C69C-5544-45DA-ABD5-765E5767FE00Q36040772-A3A9A1EF-B672-45B5-88F9-599CD1568927Q36492939-1289DC90-4B60-4331-91DA-BA7B9ECBB102Q36545015-445CC764-B6CF-4E5A-B29C-448CE71CE802Q36555922-79673DAC-9B56-4B92-BF8B-0AEE8FFBA37DQ37046633-13C3D923-BC5C-4524-9CB8-1FA47DE9925EQ37325319-0FBE9E8B-2F2B-4285-9F25-5209C013868FQ37486720-CFDC7B5D-0463-4399-80B6-1CC63E8C9496Q37691210-6BA8B2FA-EF83-4BAD-A790-ED08553BC444Q37806982-4DFAC981-343B-4942-8BF1-6CCB44B6EADDQ37946957-A495DA64-A7BD-49FF-90FC-BA465C3968E4Q38431150-8A93FAF1-167A-4876-888F-14ECC6C77A17Q38513684-1EE09B87-5DA2-4BCE-B3EB-8717E718AB4CQ38651234-063B4E3E-4007-4FCE-892E-991432CE5DBCQ40565875-BD434545-EFB8-4031-8A19-7EEFCF97C3CDQ40575037-9157F607-0E94-461F-944F-C979F122FB05Q41631036-3CC5271C-6674-4028-A40B-0EA605BF5B3AQ42284313-E559509F-A867-4026-A0C3-D0849205639DQ42985589-D06DB3CB-914E-49E2-913E-C4E50B0C23DDQ44383228-83F4AEA7-EA3B-4A9D-9B20-8D1596C190B6
P2860
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The effect of genetic polymorp ...... on phenytoin dose requirement.
@en
The effect of genetic polymorp ...... on phenytoin dose requirement.
@nl
type
label
The effect of genetic polymorp ...... on phenytoin dose requirement.
@en
The effect of genetic polymorp ...... on phenytoin dose requirement.
@nl
prefLabel
The effect of genetic polymorp ...... on phenytoin dose requirement.
@en
The effect of genetic polymorp ...... on phenytoin dose requirement.
@nl
P2093
P1476
The effect of genetic polymorp ...... on phenytoin dose requirement.
@en
P2093
Steijns LS
van Weelden MJ
van der Weide J
P304
P356
10.1097/00008571-200106000-00002
P577
2001-06-01T00:00:00Z